Article Information
PubMed
Published By
Print ISSN
Online ISSN
History
- Received for publication September 8, 2014
- Accepted for publication November 18, 2014
- Published online January 2, 2015.
Article Versions
- previous version (December 11, 2014 - 05:33).
- You are viewing the most recent version of this article.
Copyright & Usage
© 2015 by the Society of Nuclear Medicine and Molecular Imaging, Inc.
Author Information
- Ken Herrmann1,2,
- Johannes Czernin1,
- Edward M. Wolin3,
- Pawan Gupta1,
- Martin Barrio1,
- Antonio Gutierrez4,
- Christiaan Schiepers1,
- Sherly Mosessian1,
- Michael E. Phelps1 and
- Martin S. Allen-Auerbach1
- 1Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, California
- 2Department of Nuclear Medicine, University Hospital Würzburg, Würzburg, Germany
- 3Carcinoid/Neuroendocrine Tumor Program, Samuel Oschin Cancer Center, Cedars-Sinai Medical Center, Los Angeles, California; and
- 4Department of Radiological Sciences, David Geffen School of Medicine at UCLA, Los Angeles, California
- For correspondence or reprints contact: Martin S. Allen-Auerbach, Ahmanson Translational Imaging Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, 10833 Le Conte Ave., Medical Plaza 200, Suite B114-61, Los Angeles, CA 90095-7370. E-mail: mauerbach{at}mednet.ucla.edu
Statistics from Altmetric.com
Cited By...
Article usage
Jump to section
Related Articles
Cited By...
- Dual Somatostatin Receptor/18F-FDG PET/CT Imaging in Patients with Well-Differentiated, Grade 2 and 3 Gastroenteropancreatic Neuroendocrine Tumors
- Impact of 68Ga-PSMA-11 PET on Management in Patients with Biochemically Recurrent Prostate Cancer
- Current Concepts in 68Ga-DOTATATE Imaging of Neuroendocrine Neoplasms: Interpretation, Biodistribution, Dosimetry, and Molecular Strategies
- Most of the Intended Management Changes After 68Ga-DOTATATE PET/CT Are Implemented
- The Impact of Somatostatin Receptor-Directed PET/CT on the Management of Patients with Neuroendocrine Tumor: A Systematic Review and Meta-Analysis
- 68Ga-DOTATATE PET/CT Interobserver Agreement for Neuroendocrine Tumor Assessment: Results of a Prospective Study on 50 Patients
- Comparison of the Impact of 68Ga-DOTATATE and 18F-FDG PET/CT on Clinical Management in Patients with Neuroendocrine Tumors
- Safety and Efficacy of 68Ga-DOTATATE PET/CT for Diagnosis, Staging, and Treatment Management of Neuroendocrine Tumors
- 18F-FDG PET/CT and PET/MRI Perform Equally Well in Cancer: Evidence from Studies on More Than 2,300 Patients
- The Impact of 68Ga-DOTATATE PET/CT Imaging on Management of Patients with Neuroendocrine Tumors: Experience from a National Referral Center in the United Kingdom